Results 101 to 110 of about 17,377 (218)

Early‐Onset Wild‐Type Transthyretin Amyloidosis Polyneuropathy

Muscle &Nerve, Volume 74, Issue 5, Page 1471-1475, November 2026.
Chafic Karam, Kaylee Baker, Sami Khella, Brian Drachman, Pranav Chandrashekar, MacLean Nasrallah, Shunsuke Koga, Janice Pieretti   +7 more
wiley   +1 more source

Tc-HDP quantitative SPECT/CT in transthyretin cardiac amyloid and the development of a reference interval for myocardial uptake in the non-affected population

European Journal of Hybrid Imaging, 2018
Background 99mTechnetium-HDP (HDP) bone scans differentiate transthyretin (ATTR) cardiac amyloid from other infiltrative myocardial diseases. These scans are not quantitative and are assessed by comparing myocardial uptake to bone.
Stuart C. Ramsay, Karen Lindsay, William Fong, Shaun Patford, John Younger, John Atherton   +5 more
doaj   +1 more source

Multi-modality imaging in cardiac ATTR amyloidosis: agreement between echocardiography, MRI and DPD-scintigraphy [PDF]

, 2015
From First European Congress on Hereditary ATTR amyloidosisParis, France. 2-3 November 2015International audienceBackgroundThree main imaging techniques are commonly used to identify cardiac transthyretin (ATTR) amyloidosis: echocardiography, MRI and DPD
Dominique Le Guludec, Vincent Algalarrondo, Michel Slama, Teresa Antonini, Ou, Phalla, Slama, Michel, Rouzet, F., Phalla Ou, Ludivine Eliahou, Renata Chequer, François Rouzet, Le Guludec, Dominique, Antonini, Teresa, Chequer, Renata, Algalarrondo, Vincent, Eliahou, Ludivine   +15 more
core   +1 more source

Content Validation of the ATTR Amyloidosis Patient Symptom Survey: Findings from Patient and Clinician Cognitive Debriefing Interviews

Patient Related Outcome Measures, 2020
Avery A Rizio,1 Lynne E Broderick,1 Michelle K White,1 Tiffany P Quock2 1Optum Life Sciences, Patient Insights, Johnston, RI, USA; 2Prothena Biosciences Inc, South San Francisco, CA, USACorrespondence: Avery A RizioOptum Life Sciences, Patient Insights ...
Rizio AA, Broderick LE, White MK, Quock TP   +3 more
doaj  

Wild-type transthyretin amyloidosis (ATTR-wt): preliminary study on the prevalence of peripheral neuropathy in patients with ATTR-wt cardiomyopathy

reservedIntroduzione: L’amiloidosi da transtiretina wild type (ATTR-wt) è una patologia sistemica progressiva acquisita, che interessa prevalentemente i soggetti anziani di sesso maschile. La manifestazione primaria della patologia è lo sviluppo di una
RAMPOGNA, MATILDE
core  

Characterization of heterozygous ATTR Tyr114Cys amyloidosis-specific induced pluripotent stem cells

Heliyon
Hereditary transthyretin (TTR) amyloidosis (ATTRv amyloidosis) is autosomal dominant and caused by mutation of TTR gene. Heterozygous ATTR Tyr114Cys (p.Tyr134Cys) amyloidosis is a lethal disease with a life expectancy of about 10 years after onset of the
Kenta Ouchi, Kaori Isono, Yuki Ohya, Nobuaki Shiraki, Masayoshi Tasaki, Yukihiro Inomata, Mitsuharu Ueda, Takumi Era, Shoen Kume, Yukio Ando, Hirofumi Jono   +10 more
doaj   +1 more source

Exploring Transthyretin Amyloidosis Through Protein Interaction Network Analysis

Biophysica
Transthyretin amyloidosis (ATTR) is a human systemic disorder, caused by deposition of transthyretin amyloid fibrils in various organs and tissues. Significant difficulties in studying ATTR include heterogeneous symptomatology, its complex pathological ...
Maria-Eleni P. Iatridi, Avgi E. Apostolakou, Zoi I. Litou, Vassiliki A. Iconomidou   +3 more
doaj   +1 more source

Best Practices in Nuclear Imaging for the Diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in KSA: The Eagle Eyes of Local Experts

Diagnostics
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a complex and serious form of heart failure caused by the accumulation of transthyretin amyloid protein in the heart muscle. Variable symptoms of ATTR-CM can lead to a delayed diagnosis.
Abdullah Alqarni, Ahmed Aljizeeri, Aquib Mohammadidrees Bakhsh, Hossam Ahmed Maher El-Zeftawy, Hussein R. Farghaly, Mukhtar Ahmed M. Alqadhi, Mushref Algarni, Zain Mohammed Asiri, Ahmed Osman, Haya Haddadin, Islam Alayary, Mouaz H. Al-Mallah   +11 more
doaj   +1 more source

Evolution of patient characteristics and outcomes in ATTR-CM clinical trials: A systematic review.

Background: Over the past decade, advancements in awareness, diagnosis, and new treatment options for transthyretin amyloid cardiomyopathy (ATTR-CM) have likely influenced the characteristics of patient populations enrolled in clinical trials.
Betts, Marissa, Nativi-Nicolau, Jose, Masri, Ahmad, Dev, Sandesh, Hennum, Liana, Wright, Richard, Falvey, Heather, Lavoie, Louis, Tamby, Jean-François   +8 more
core   +1 more source

Right Ventricular Free Wall Strain Predicts ATTR Prognosis as Well as Biomarker- Based Staging Systems

International audienceAims: The diagnosis of transthyretin amyloidosis (ATTR) significantly impacts the management and prognosis of patients initially presenting with heart failure (HF).
Donal, Erwan, Lee, K Charlotte, Bourg, Corentin, l'Official, Guillaume, Al Wazzan, A, Antonelli, Jerome, Marut, Benjamin, Istratoaie, Sabina   +7 more
core   +1 more source